Clinical Research Directory
Browse clinical research sites, groups, and studies.
TDM for Optimized Outcome in Patients With mRCC.
Sponsor: Niels Fristrup
Summary
The purpose of this observational study is to assess the role of plasma concentration monitoring of treatment drugs for patients with metastatic renal cell carcinoma (mRCC) in terms of efficacy and side effects. It furthermore holds microbiome characterization of CPI-treated patients. Furthermore, the investigators examines the role of anti-drug antibodies and receptor polymorphisms in CTLA-4 and PD-1 receptors in treatment failure among patients with mRCC treated with check point immunotherapy (CPI). Moreover, polymorphisms in the UGT1A1 gene will be correlated with the pazopanib treatment dose.
Official title: Therapeutic Drug Monitoring for Optimized Outcome in Patients With Metastatic Renal Cell Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2020-11-01
Completion Date
2029-08-31
Last Updated
2025-03-05
Healthy Volunteers
No
Interventions
Measurement of concentration of active metabolite in cancer treatment.
Medical treatment for metastatic renal cell carcinoma with axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib and ipilimumab and nivolumab.
Locations (1)
Department of Oncology, Aarhus University Hospital
Aarhus, Danmark, Denmark